Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Merck
Moodys
Dow
McKinsey

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Onartuzumab


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Onartuzumab?

Onartuzumab is an investigational drug.

There have been 15 clinical trials for Onartuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Stomach Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and M.D. Anderson Cancer Center.

There are seventeen US patents protecting this investigational drug and five hundred and thirty international patents.

Recent Clinical Trials for Onartuzumab
TitleSponsorPhase
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored StudyHoffmann-La RochePhase 3
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)Genentech, Inc.Phase 1/Phase 2
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)M.D. Anderson Cancer CenterPhase 1/Phase 2

See all Onartuzumab clinical trials

Clinical Trial Summary for Onartuzumab

Top disease conditions for Onartuzumab
Top clinical trial sponsors for Onartuzumab

See all Onartuzumab clinical trials

US Patents for Onartuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Onartuzumab ⤷  Try it Free Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) ⤷  Try it Free
Onartuzumab ⤷  Try it Free Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ⤷  Try it Free
Onartuzumab ⤷  Try it Free Cancer treatment with c-met antagonists and correlation of the latter with HGF expression Genentech, Inc. (South San Francisco, CA) ⤷  Try it Free
Onartuzumab ⤷  Try it Free Methods of treating glioblastoma multiforme using ibudilast MediciNova, Inc. (La Jolla, CA) ⤷  Try it Free
Onartuzumab ⤷  Try it Free Method for predicting efficacy of c-Met inhibitor SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) ⤷  Try it Free
Onartuzumab ⤷  Try it Free Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) ⤷  Try it Free
Onartuzumab ⤷  Try it Free Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Onartuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Onartuzumab Canada CA2900764 2033-02-08 ⤷  Try it Free
Onartuzumab European Patent Office EP2954056 2033-02-08 ⤷  Try it Free
Onartuzumab Hong Kong HK1218930 2033-02-08 ⤷  Try it Free
Onartuzumab Japan JP2016509014 2033-02-08 ⤷  Try it Free
Onartuzumab World Intellectual Property Organization (WIPO) WO2014124326 2033-02-08 ⤷  Try it Free
Onartuzumab Australia AU2013220749 2032-02-15 ⤷  Try it Free
Onartuzumab Brazil BR112014019627 2032-02-15 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Merck
Moodys
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.